This year’s American Society of Hematology (ASH) Annual Meeting was filled with fascinating new treatments and treatment combinations which left me thinking that there is so much more information to...
The Myeloma Puzzle
read more
Linda Huguelet
Linda was diagnosed with multiple myeloma at 46. She has been co-leading the Chattanooga Multiple Myeloma Networking group with her husband since February 2011. Linda has received a variety of treatments including her most recent, CAR-T, in late June 2023. After almost 18 months, she remains in remission and treatment free!
Linda has found it important to exercise throughout her myeloma journey. She is currently building her core strength so that she can continue walking and gardening.
Excited to learn of the latest developments in myeloma care, Linda will be attending ASH for the 12th time with the IMF, focusing on treatment options for relapsed/refractory patients, with a concentration on bi-specifics and real-world data.
Follow Linda on X: @LindaMYELOMA
Support Group Website: Chattanooga Area Multiple Myeloma Networking Group
More Questions Than Answers
After yesterday's abstract sessions, I think I have more questions than answers. Not exactly what I was hoping for, but questions do lead to more investigation and knowledge. There was a lot of...
Addressing Current Questions and Controversies
Friday evening (Eastern time), I attended one of the best symposiums I’ve seen in my 12 years of attending the American Society of Hematology (ASH) Annual Meeting. Sagar Lonial, MD moderated a panel...
Maximizing Treatment Free Time
Over my 14 years as a myeloma patient, I’ve been through 5 lines of therapy. Until my Carvykti (ciltacabtagene autoleucel) CAR T-cell therapy in the summer of 2023, I always needed to be on some...